| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $613.8M | — | -2.5% |
| R&D Expense | $67.9M | — | -3.0% |
| SG&A Expense | $102.1M | — | -9.5% |
| Operating Income | -$61.8M | — | +48.8% |
| Pre-tax Income | -$60.8M | — | +45.3% |
| Income Tax | $3.0M | — | +116.4% |
| Net Income | -$63.8M | — | +31.4% |
| EPS (Basic) | -$0.36 | — | +32.1% |
| EPS (Diluted) | -$0.36 | — | +32.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $750.7M | -3.9% | -37.1% |
| Accounts Receivable | $213.6M | +10.8% | -8.3% |
| Inventory | $31.6M | -17.4% | -17.0% |
| Current Assets | $1.13B | +1.2% | -29.3% |
| Total Assets | $2.81B | -1.8% | -18.5% |
| Current Liabilities | $404.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $9.5M | — | -40.2% |
| Capital Expenditures | $1.7M | — | -39.1% |
| Investing Cash Flow | -$36.5M | — | +70.4% |
| Financing Cash Flow | -$2.4M | — | -418.5% |
| Free Cash Flow | $7.9M | — | -40.5% |
| -57.5% |
| Total Liabilities | $1.47B | -0.1% | -27.1% |
| Stockholders' Equity | $1.34B | -3.6% | -6.4% |